Johnson & Johnson JNJ SPXR3KPHARMA

Q: What is the current share price of Johnson & Johnson (JNJ)?

As of 2026-09-07 16:24 PDT, Johnson & Johnson (JNJ) trades at $275.23 on NYSE. Its 52-week range is $170.17 to $278.43.

Q: What is the market capitalisation of JNJ?

Johnson & Johnson (JNJ) has a market capitalisation of $663.28B on NYSE.

Q: What is the P/E ratio of JNJ?

JNJ trades at a trailing price-to-earnings (P/E) ratio of 31.97. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 7.35.

Q: Does JNJ pay a dividend?

Johnson & Johnson (JNJ) currently offers a dividend yield of 2.09%.

Q: What is the return on equity (ROE) of JNJ?

JNJ has a return on equity (ROE) of 25.74%. Its return on capital employed (ROCE) is 14.88%.

Q: Is JNJ a good stock to buy?

This page provides a data-driven analysis of Johnson & Johnson (JNJ), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Drug Manufacturers - General · United States

https://www.jnj.com

Company Profile ↓

$275.23

+61.74% 1Y

Mkt Cap$663.28B

P/E31.97

P/B7.35

Div. Yield2.09%

52W High$278.43

52W Low$170.17

Book Value$35.28

EPS (TTM)$8.61

Company Overview

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 25.7%, reflecting efficient use of shareholder capital.

Healthy Margins

Maintains a net profit margin of 21.5%.

Dividend Income

Offers a dividend yield of 2.09%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $94.19B (+6.0% YoY); net profit $26.80B.
Trailing 12 Months Year-on-year growth — revenue +6.6%, earnings -0.9%.
5-Year Trend Long-term compounding — revenue CAGR 2.4%, profit CAGR 4.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	2.43%
1 Year:	6.60%

Compounded Profit Growth

5 Years:	4.76%
1 Year:	-0.90%

Stock Price Performance

1 Year:	+61.74%
6 Months:	+15.71%
3 Months:	+18.82%
1 Month:	+7.63%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 97% of range

$170.17 $278.43

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)61.22 · Neutral

Price Performance

1M+7.63%

3M+18.82%

6M+15.71%

1Y+61.74%

Valuation vs Sector

P/E of 31.97 is above the sector median of 25.17 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Strong return on equity of 25.7%.
Excellent profit margin of 21.5%.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

31.97

Industry PE

25.17

Forward P/E

22.36

PEG Ratio

4.24

Book Value

$35.28

Price to Book

7.35

P/S

6.38

EV/EBITDA

18.73

Dividend Yield

2.09%

Growth (CAGR)

Revenue 5Y

2.43%

Profit 5Y

4.76%

Revenue (YoY)

6.60%

Earnings (YoY)

-0.90%

Profitability & Returns

ROCE

14.88%

ROE

25.74%

ROA

8.60%

Profit Margin

21.48%

Op Margin

29.19%

Gross Margin

68.14%

EPS (Latest Qtr)

$2.27

EPS (TTM)

$8.61

Balance Sheet & Liquidity

Debt/Equity

0.58

Quick Ratio

0.72

Current Ratio

1.09

Debt

$49.04B

Total Assets

$201.06B

Current Assets

$55.62B

Working Capital

$1.50B

Ownership

Promoter Holding

0.05%

Chg in Prom Hold

0.00%

FII / Inst Holding

76.87%

Chg in FII Hold

-0.04%

Financial Snapshot

Enterprise Value

$663.28B

Total Revenue (TTM)

$97.93B

EBITDA

$34.87B

Free Cash Flow

$16.89B

Operating Cash Flow

$27.61B

Shares Outstanding

2.41B

Gross Margin

68.14%

Payout Ratio

60.79%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
4	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
5	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
6	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
7	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
8	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	608.52	32.79	$225.00B	0.32%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Apr 2016	Jul 2016	Oct 2016	Jan 2017	Apr 2017	Jul 2017	Oct 2017	Dec 2017	Apr 2018	Jul 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Apr 2021	Jul 2021	Oct 2021	Apr 2022	Jul 2022	Oct 2022	Jan 2023	Apr 2023	Jul 2023	Oct 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	17.77B	18.84B	19.65B	20.20B	20.01B	20.83B	20.35B	20.39B	20.02B	20.56B	20.73B	20.75B	20.69B	18.34B	21.08B	22.32B	23.31B	23.34B	19.84B	20.21B	20.00B	19.94B	20.89B	21.52B	21.35B	21.39B	21.38B	22.45B	-	-	21.89B	23.74B	23.99B	24.56B	24.06B	25.31B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.36B	7.63B	7.30B	7.97B	8.11B	-
Gross Profit	12.15B	13.15B	12.33B	12.57B	12.36B	12.99B	12.72B	12.94B	13.39B	13.90B	13.76B	13.43B	13.41B	13.62B	13.86B	13.61B	13.63B	11.76B	14.11B	15.26B	15.72B	16.09B	13.82B	13.89B	13.82B	13.86B	14.21B	15.06B	14.74B	14.60B	14.87B	15.58B	-	-	14.54B	16.11B	16.69B	16.60B	15.96B	17.26B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8.34B	9.40B	9.59B	11.01B	9.56B	-
Operating Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.20B	6.71B	7.10B	5.59B	6.39B	-
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15.61B	8.74B	9.52B	7.19B	8.27B	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	204.00M	308.00M	245.00M	214.00M	272.00M	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13.63B	6.49B	7.49B	4.97B	5.99B	-
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.63B	954.00M	2.34B	-150.00M	755.00M	-
Net Income	4.46B	4.00B	4.27B	3.81B	4.42B	3.83B	3.76B	-10.71B	4.37B	3.95B	3.93B	3.04B	3.75B	5.61B	1.75B	4.01B	5.80B	3.63B	3.55B	6.20B	6.28B	3.67B	5.15B	4.81B	4.46B	3.52B	-68.00M	5.14B	26.03B	4.05B	3.25B	4.69B	-	-	11.00B	5.54B	5.15B	5.12B	5.24B	5.53B
Diluted EPS	1.59	1.43	1.53	1.38	1.61	1.40	1.37	-3.99	1.60	1.45	1.44	1.12	1.39	2.08	0.66	1.50	2.17	1.36	1.33	2.32	2.35	1.37	1.93	1.80	1.68	1.33	-0.03	1.96	10.21	1.67	1.34	1.93	-	-	4.54	2.29	2.12	2.10	2.14	2.27

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Jan 2010	Jan 2011	Jan 2012	Dec 2012	Dec 2013	Dec 2014	Jan 2016	Jan 2017	Dec 2017	Dec 2018	Dec 2019	Jan 2021	Jan 2022	Jan 2023	Dec 2023	Dec 2024	Dec 2025
Revenue	61.09B	63.75B	61.90B	61.59B	65.03B	67.22B	71.31B	74.33B	70.07B	71.89B	76.45B	81.58B	82.06B	82.58B	78.74B	79.99B	85.16B	88.82B	94.19B
Gross Profit	43.34B	45.24B	43.45B	42.80B	44.67B	45.57B	48.97B	51.59B	48.54B	50.10B	51.01B	54.49B	54.50B	54.16B	55.34B	55.39B	58.61B	61.35B	63.94B
Operating Income	-	-	16.58B	17.70B	13.77B	14.96B	16.41B	21.59B	-	-	-	-	-	-	-	-	-	-	-
Net Income	-	-	-	13.33B	9.67B	10.85B	13.83B	16.32B	15.41B	16.54B	1.30B	15.30B	15.12B	14.71B	20.88B	17.94B	35.15B	14.07B	26.80B
Diluted EPS	3.63	4.57	4.40	4.78	3.49	3.86	4.81	5.70	5.48	5.93	0.47	5.61	5.63	5.51	7.81	6.73	13.72	5.79	11.03
R&D Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	483.00M	1.84B	109.00M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2006	Dec 2007	Dec 2008	Jan 2010	Jan 2011	Jan 2012	Dec 2012	Dec 2013	Dec 2014	Jan 2016	Jan 2017	Dec 2017	Dec 2018	Dec 2019	Jan 2021	Dec 2021	Jan 2022	Dec 2022	Jan 2023	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	84.91B	94.68B	102.91B	113.64B	121.35B	132.68B	130.36B	133.41B	141.21B	157.30B	152.95B	157.73B	174.89B	-	182.02B	187.38B	187.38B	167.56B	180.10B	199.21B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	55.29B	-	53.49B	55.89B	55.62B
Cash & Equivalents	4.08B	7.77B	10.77B	15.81B	19.36B	24.54B	14.91B	20.93B	14.52B	13.73B	18.97B	17.82B	18.11B	17.30B	13.98B	-	14.49B	12.89B	12.89B	21.86B	24.11B	19.71B
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.27B	-	11.18B	12.44B	14.19B
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14.04B	-	14.87B	14.84B	17.18B
Total Liabilities	-	-	42.40B	44.09B	46.33B	56.56B	56.52B	58.63B	60.61B	62.26B	70.79B	97.14B	93.20B	98.26B	111.62B	-	108.00B	110.57B	110.57B	98.78B	108.61B	117.67B
Current Liabilities	-	-	20.85B	21.73B	23.07B	22.81B	24.26B	25.68B	25.03B	27.75B	26.29B	30.54B	31.23B	35.96B	42.49B	-	45.23B	55.80B	55.80B	46.28B	50.32B	54.13B
Long Term Debt	-	-	8.12B	8.22B	9.16B	12.97B	11.49B	13.33B	15.12B	12.86B	22.44B	30.68B	27.68B	26.49B	32.63B	-	29.98B	26.89B	26.89B	25.88B	30.65B	39.44B
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	39.64B	-	29.33B	36.63B	47.93B
Total Equity	39.32B	43.32B	42.51B	50.59B	56.58B	57.08B	64.83B	74.05B	69.75B	71.15B	70.42B	60.16B	59.75B	59.47B	63.28B	-	74.02B	76.80B	76.80B	68.77B	71.49B	81.54B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.12B	-	3.12B	3.12B	3.12B

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Jan 2010	Jan 2011	Jan 2012	Dec 2012	Dec 2013	Dec 2014	Jan 2016	Jan 2017	Dec 2017	Dec 2018	Dec 2019	Jan 2021	Jan 2022	Jan 2023	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	15.02B	14.97B	16.57B	16.39B	14.30B	15.40B	17.41B	18.71B	19.57B	18.77B	21.06B	22.20B	23.42B	23.54B	23.41B	21.19B	22.79B	24.27B	24.53B
Investing Cash Flow	-5.91B	-4.19B	-7.60B	-7.85B	-4.61B	-4.51B	-5.10B	-12.30B	-7.74B	-4.76B	-14.87B	-3.17B	-6.19B	-20.82B	-8.68B	-12.37B	878.00M	-18.60B	-23.59B
Financing Cash Flow	-5.70B	-7.46B	-4.09B	-4.98B	-4.45B	-20.56B	-6.09B	-12.50B	-11.14B	-8.55B	-7.67B	-18.51B	-18.02B	-6.12B	-14.05B	-8.87B	-15.82B	-3.13B	-5.54B
Capital Expenditure	-2.94B	-3.07B	-2.37B	-2.38B	-2.89B	-2.93B	-3.60B	-3.71B	-3.46B	-3.23B	-3.28B	-3.67B	-3.50B	-3.35B	-3.65B	-4.01B	-4.54B	-4.42B	-4.83B
Free Cash Flow	12.08B	11.91B	14.21B	14.00B	11.40B	12.46B	13.82B	15.00B	16.11B	15.54B	17.78B	18.53B	19.92B	20.19B	19.76B	17.18B	18.25B	19.84B	19.70B
Share Buybacks	5.61B	6.65B	2.13B	2.80B	2.52B	12.92B	3.54B	7.12B	5.29B	8.98B	6.36B	5.87B	6.75B	3.22B	3.46B	6.04B	5.05B	2.43B	5.95B

Ratios (Annual)

Figures in %.

Metric	Dec 2007	Dec 2008	Jan 2010	Jan 2011	Jan 2012	Dec 2012	Dec 2013	Dec 2014	Jan 2016	Jan 2017	Dec 2017	Dec 2018	Dec 2019	Jan 2021	Jan 2022	Jan 2023	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	70.9%	71.0%	70.2%	69.5%	68.7%	67.8%	68.7%	69.4%	69.3%	69.7%	66.7%	66.8%	66.4%	65.6%	70.3%	69.3%	68.8%	69.1%	67.9%
Operating Margin %	-	-	26.8%	28.7%	21.2%	22.2%	23.0%	29.0%	-	-	-	-	-	-	-	-	-	-	-
Net Margin %	-	-	-	21.7%	14.9%	16.1%	19.4%	22.0%	22.0%	23.0%	1.7%	18.8%	18.4%	17.8%	26.5%	22.4%	41.3%	15.8%	28.5%
ROE %	-	-	-	23.6%	16.9%	16.7%	18.7%	23.4%	21.7%	23.5%	2.2%	25.6%	25.4%	23.3%	28.2%	23.4%	51.1%	19.7%	32.9%
ROCE %	-	-	22.7%	22.2%	15.2%	15.4%	15.3%	20.5%	-	-	-	-	-	-	-	-	-	-	-

Shareholding Pattern

Insiders

0.05%

Institutions

76.87%

Public Float

76.91%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	8.80%	212.10M	$56.85B
2	Vanguard Capital Management LLC	6.52%	157.23M	$42.14B
3	State Street Corporation	5.55%	133.78M	$35.86B
4	Vanguard Portfolio Management LLC	2.67%	64.37M	$17.25B
5	Geode Capital Management, LLC	2.45%	59.09M	$15.84B
6	JPMORGAN CHASE & CO	2.42%	58.30M	$15.63B
7	Morgan Stanley	1.86%	44.81M	$12.01B
8	NORGES BANK	1.32%	31.83M	$8.53B
9	State Farm Mutual Automobile Insurance Co	1.31%	31.59M	$8.47B
10	Northern Trust Corporation	1.19%	28.79M	$7.72B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for JNJ

Google News Fri, 04 Sep 2026

Was JNJ Stock Rally Actually Its Own? - Trefis

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxOZnFjMXo2cm52djdIZFVDdFJPV3h4azRYQWR2d2NrVV9PUWtMcFgxY19yWXZwSDBLTHJVcWt2ek5weDZNam85SlZ1MVp4aThGeE9maDVSN2ZDOFNtNmlld0p2YTBxQ1B3aFBVbHlPTXMtMG9WcEZqOFQ1M19DYXBWUFBfQ0ZUWVZwajg4d2…

Google News Mon, 07 Sep 2026

Which Defensive Stock Has Dominated in 2026: Coca-Cola, Johnson & Johnson, or Procter & Gamble? - 24/7 Wall St.

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPUW9IZXpPSzl0TkVlNXNUNl9TVlNvN0xiV2M0UjVtUFZ5WnhmNDNJZkpVYjN4RWlNUzloS2NiTVFhaE9xSl9Tc25aQm1LbENyRUZCbWhGZDNqZ2hPcWItZzJBc0RqZGoxQnVlMnYtRHJ3SGlFRzB1LUcya2FpMHozZ0g3YVdsTlBSUjRCc3…

Google News Mon, 07 Sep 2026

Lilly vs. J&J: Betting on Breakout Growth or Built-In Stability? - The Globe and Mail

<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxPQVV1bmNrNnlZWUU1NS1xblN2VnJnckNCWmdUTlNmYXhBWmQteU1hSVBmbG8weF8yb0NsWjFxaTc1NkwwYWhNaVhmZ3dqcXoxX0F1cHZlWnZHNUNNVUpWX3FBbWZmLWxHb2o0LTBnSUJCbEFkek9WbUJLMUpYeXdfZ043VGtPUnlic2pMUV…

Google News hu, 20 Aug 2026

Johnson & Johnson Just Sent Shareholders an Important 11-Word Message About Its Future - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxPcUhRc3Z3Z054SExtQ0R0X0RJc1BwaEJhMU9CdWVVcVhTSWRsMklIWXUzVFVOSEw1NmFEUS1HXzZEbjVsSUdwZ3JkWGhSeFk2a2JlalEtZGVoR1dUZXRSSEtDRzlZalQxMzJULWtzdjJBeGVWakE0VEJ5RHltV2ZlUU5oaWQ2NVljdFYwTH…

Google News Sun, 06 Sep 2026

NAVN, JNJ, CRWD Stocks Hit 52-Week Highs Last Week: What's Driving The Surge? - Stocktwits

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxQMzJrSkRFVTNGWFBYeUtSWnp4RXRXVVlsYWhUeHljM25vaHFoWUhMUk1iZ00tdzl5SnlselpBbV9zdVNiX3JOaFByZUV4OG5lb3NuUkVJN3NFVWd1ZHY5RGl5Vmp4c1lFNllvcjI1RFBmZVV0MUtKNVVKclk3djlNbWRDcWRVRmE0RlNHeW…

Google News Wed, 02 Sep 2026

J&J stock at all-time high as UBS assumes at Buy (JNJ:NYSE) - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxOdG9YR2psVjJtRGk0OW9za3dMQ0Q3QS1FSHNXSFFwLVd4TGR4cm9ISWpCNzdOOWxtX1pKR2JTaUhxRktEVTM0TTNxenNvdHdobF9WUXAxMGllMUpSbzNUZHE1R1RIT0c0ZXQ4VDBmWWJyb0ZMaURVWi15R0tZNmxCdGhNWHZGUQ?oc=5" t…

JNJ — Frequently Asked Questions

What is the current share price of Johnson & Johnson (JNJ)?

As of 2026-09-07 16:24 PDT, Johnson & Johnson (JNJ) trades at $275.23 on NYSE. Its 52-week range is $170.17 to $278.43.

What is the market capitalisation of JNJ?

Johnson & Johnson (JNJ) has a market capitalisation of $663.28B on NYSE.

What is the P/E ratio of JNJ?

JNJ trades at a trailing price-to-earnings (P/E) ratio of 31.97. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 7.35.

Does JNJ pay a dividend?

Johnson & Johnson (JNJ) currently offers a dividend yield of 2.09%.

What is the return on equity (ROE) of JNJ?

JNJ has a return on equity (ROE) of 25.74%. Its return on capital employed (ROCE) is 14.88%.

Is JNJ a good stock to buy?

This page provides a data-driven analysis of Johnson & Johnson (JNJ), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Johnson & Johnson JNJ SPXR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Was JNJ Stock Rally Actually Its Own? - Trefis

Which Defensive Stock Has Dominated in 2026: Coca-Cola, Johnson & Johnson, or Procter & Gamble? - 24/7 Wall St.

Lilly vs. J&J: Betting on Breakout Growth or Built-In Stability? - The Globe and Mail

Johnson & Johnson Just Sent Shareholders an Important 11-Word Message About Its Future - Yahoo Finance

NAVN, JNJ, CRWD Stocks Hit 52-Week Highs Last Week: What's Driving The Surge? - Stocktwits

J&J stock at all-time high as UBS assumes at Buy (JNJ:NYSE) - Seeking Alpha

JNJ — Frequently Asked Questions

What is the current share price of Johnson & Johnson (JNJ)?

What is the market capitalisation of JNJ?

What is the P/E ratio of JNJ?

Does JNJ pay a dividend?

What is the return on equity (ROE) of JNJ?

Is JNJ a good stock to buy?

Explore More